Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treatment of diabetes using peptide analogues of insulin

a technology of peptide analogues and insulin, which is applied in the direction of peptide/protein ingredients, extracellular fluid disorder, metabolic disorders, etc., can solve the problems of generating neutralizing antibodies, difficulty in maintaining proper dosage, and variety of hypoglycemic side effects

Inactive Publication Date: 2006-02-23
NEUROCRINE BIOSCIENCES INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While administration of insulin provides significant benefits to patients suffering from diabetes, the short serum half-life of insulin creates difficulties for maintaining proper dosage.
The use of insulin also can result in a variety of hypoglycemic side-effects and the generation of neutralizing antibodies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treatment of diabetes using peptide analogues of insulin
  • Methods for treatment of diabetes using peptide analogues of insulin
  • Methods for treatment of diabetes using peptide analogues of insulin

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Peptides

[0051] This Example illustrates the synthesis of representative peptide analogues.

[0052] Peptides were synthesized by solid phase methodology on a peptide synthesizer (Beckman model 990). Peptides with an amidated carboxyl-terminus were prepared with a p-methylbenzhydrylamine resin (MBHA resin); for peptides with a free carboxyl-terminus, a Merrifield resin coupled with the appropriately protected amino acid was used. Both resins were obtained from Bachem Fine Chemicals (Torrance, Calif.). Derivatized amino acids (Bachem Fine Chemicals) used in the synthesis were of the L-configuration unless specified otherwise, and the N-alpha-amino function protected exclusively with the t-butyloxycarbonyl group. Side-chain functional groups were protected as follows: benzyl for serine and threonine; cyclohexyl for glutamic acid and aspartic acid; tosyl for histidine and arginine; 2-chlorobenzyloxycarbonyl for lysine and 2-bromobenzyloxycarbonyl for tyrosine. Coupling of ...

example 2

Long-Term T Cell Lines

[0053] This Example illustrates the preparation of long-term insulin-specific NOD T cell lines.

[0054] Insulin specific NOD T cell lines were established by culturing lymphocytes isolated from islet-infiltrating populations by in vitro stimulation with either porcine insulin at 25 μg / ml and irradiated NOD islet cells in the presence of irradiated NOD spleen cells as antigen presenting cells and cytokines. To obtain the infiltrating lymphocytes the following procedures were performed (see Wegmann et al., Eur. J. Immunol. 24:1853, 1994): the pancreas from the NOD mouse was digested with collagenase and individual islets were isolated manually. The infiltrating lymphocytes were then obtained by mild trypsin digestion of the islets. The insulin specific T cell lines or clones were propagated by serial stimulation in the presence of NOD spleen cells, porcine insulin and lymphokines. Clones were obtained by limiting dilution of the B chain (9-23) specific T cell lin...

example 3

Effect of Peptide Analogues on Proliferation of Insulin-Specific NOD T Cell Clones

[0055] This Example illustrates the effect of representative peptide analogues on T cell proliferation.

[0056] Insulin B chain (9-23) (SEQ ID NO:2) specific mouse (NOD) T cell clones were isolated from infiltrated islets as described in Example 2. Peptide analogues with single alanine substitutions were prepared as described in Example 1. The effect of each analogue on T cell proliferation was then evaluated using an assay performed in 96-well flat bottom microtiter plates (see Daniel et al., Eur. J. Immunol. 25:1056, 1995). Briefly 25,000 T cell clones along with 1 million irradiated NOD spleen cells were cultured in the presence of 50 μg / ml of insulin B chain 9-23 peptide or any of the alanine substituted peptides listed below in triplicate sets. The plates were incubated for a total of 72 hours in 7% carbon dioxide atmosphere with a pulse of 1 μCi / well of tritiated thymidine for the last 6-8 hours ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
compositionsaaaaaaaaaa
liquidaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and / or 16, and may be additionally be altered at position 19 and / or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 339,160, filed Jan. 8, 2003, now U.S. Pat. No. 6,933,274, which application is a continuation of Ser. No. 09 / 787,140, filed Jun. 7, 2001, now U.S. Pat. No. 6,562,942, which is a National Stage Application of PCT / US99 / 03915 (35 U.S.C. 371), international filing date of Feb. 23, 1999, which claims foreign priority benefits under 35 U.S.C. 119 from U.S. application Ser. No. 09 / 028,156, filed Feb. 23, 1998, now abandoned, all of which are incorporated herein by reference in their entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates generally to peptide analogues of insulin, and more specifically to methods for treating diabetes using peptide analogues derived from residues 9-23 of human insulin B chain. [0004] 2. Description of the Related Art [0005] Insulin dependent diabetes mellitus (IDDM) is an organ specific ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/28A61K38/00C07K14/62
CPCA61K38/00C07K14/622C07K14/62C07K7/08
Inventor GAUR, AMITABHLING, NICHOLASCONLON, PAUL
Owner NEUROCRINE BIOSCIENCES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com